Adams, H. C., Stevenaert, F., Krejcik, J., Van der Borght, K., Smets, T., Bald, J., . . . Casneuf, T. (2018). High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. Cytometry A.
シカゴスタイル引用形Adams, Homer C., et al. "High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated With Daratumumab Demonstrates Immune Modulation As a Novel Mechanism of Action." Cytometry A 2018.
MLA引用形式Adams, Homer C., et al. "High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated With Daratumumab Demonstrates Immune Modulation As a Novel Mechanism of Action." Cytometry A 2018.